Business Wire

Key UK SEP Patent Win for TQ Delta

Jaa

TQ Delta LLC, a technology development and licensing firm, secured a judgment on March 18 by the High Court of Justice of England and Wales immediately enjoining ZyXEL Communications UK Ltd and its Danish parent company, ZyXEL Communications A/S, from further infringement of TQ Delta's European Patent (UK) 1 453 268.

TQ Delta's patent relates to Digital Subscriber Line ("DSL") technology. In an earlier judgment, handed down on March 12, the Court found that the patent was valid and essential to the operation of ADSL2 and VDSL2. In that judgment, the Court held that the ZyXEL defendants have infringed and continue to infringe the patent. The Court also found that a second patent would have also been essential and infringed but was invalid.

In its judgment earlier this week, the Court also found that the ZyXEL defendants were "holding out" against taking a licence to TQ Delta's portfolio of patents relating to DSL. It granted an immediate injunction and costs against the ZyXEL defendants with an interim payment of more than £1 million. The Court rejected the ZyXEL defendants' requests for a stay of the injunction and to appeal both the grant of the injunction and the refusal of a stay. The ZyXEL defendants could still apply to the Court of Appeal for permission to appeal but whether they will do so remains to be seen.

Abha Divine, Managing Director of TQ Delta said “These decisions re-affirm the high quality of our patented inventions, which we believe represent important, foundational IP for the communications industry resulting from years long participation in the ITU standards setting committee.”

TQ Delta was represented by the award-winning IP team at the international law firm, Gowling WLG. The team is expert in telecommunications technology and "standard essential" patent litigation.

TQ Delta is very pleased with the decision that its patent is valid, infringed, and essential and with the grant of an immediately effective injunction,” said Alexandra Brodie, the partner-in-charge of the litigation. “This is TQ Delta's first action in the UK and is a significant win, reinforcing the importance of TQ Delta's DSL portfolio.”

The infringed patent is part of TQ Delta’s global portfolio of hundreds of patent assets that are applicable to communications technologies and standards, including DSL. “This portfolio has a deep history and we continue to invest in developing it to solve current and emerging technological challenges,” said Divine.

About TQ Delta

TQ Delta is a technology development and licensing company aimed at providing needed solutions for the communications industry and beyond. The company’s technical investments span nearly two decades of contributions and innovation in the field of communications. TQ Delta’s technologies are used in leading products and services worldwide spanning broadband communications and media distribution. For more information, visit http://www.tqdelta.com.

Contact information

Scott Krady
Magnitude, Inc.
scott@magnitudegrowth.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Immersion Signs Agreement With TDK Electronics Bringing Haptics Design and Marketing to PowerHap Piezo Actuators24.4.2019 15:30:00 EESTTiedote

Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, announced that it has signed an agreement with TDK Corp. (TSE:6762) subsidiary TDK Electronics for the design and marketing of haptic feedback for TDK PowerHap™ piezo actuators. Under the agreement, Immersion will include TDK’s actuators in reference designs for automotive, industrial and other markets. Immersion will also certify the components for use with its software products. This will enable TDK’s customers in a wide variety of markets to rapidly implement cutting-edge haptic solutions with its high-performance actuators. With 25 years in the field of touch technology, Immersion brings together the art of design and the precise science behind haptic feedback in actuators and ICs. The company connects the haptic ecosystem through the certification of haptic components, helping partners like TDK and their customers maintain consistency and high-fidelity haptic experiences across de

Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities24.4.2019 15:30:00 EESTTiedote

Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies, including Yescarta® (axicabtagene ciloleucel), Kite’s first commercially available CAR T cancer therapy, and investigational T cell receptor (TCR) cell therapies being evaluated in solid tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005257/en/ “This new facility in Frederick County builds on our substantial technical capabilities and rapid progress in making personalized CAR T and TCR cell therapies for people with cancer. As we advance our industry-leading cell therapy pipeline and seek to help a growing number of people with cancer, expanding and investing in our manufacturing capabilities is essentia

SugarCRM Announces Game-Changing Product Enhancements to Accelerate Growth, Improve Business Performance and Deliver Exceptional Customer Experiences24.4.2019 15:00:00 EESTTiedote

SugarCRM Inc.®, the company that helps organizations build better business relationships, today announced several new platform capabilities to help companies to accelerate their business growth. These new capabilities will enable them to resolve customer issues quickly, collaborate more effectively, make faster and more informed decisions about their customers, eliminate time-consuming manual processes, expand real-time mobile access to critical customer information – and do all of this on the new, blazing-fast Sugar 9 platform. “With these significant enhancements, our customers can now collaborate and communicate more effectively, know more about their customers to quickly make better decisions and confidently transact more business with faster quotes, more automation and rock-solid SOC 2 compliance. Most importantly, we have boosted system performance to new heights, enabling customers to process up to 70% more transactions without investing in new hardware,” says Rich Green, chief

USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations24.4.2019 15:00:00 EESTTiedote

Aptorum Group Limited (Nasdaq: APM), Aeneas Capital Limited, and A*ccelerate Technologies Pte Ltd, the enterprise office of the Agency for Science, Technology and Research (A*STAR), have signed a USD$90 million agreement to co-create local deep tech start-ups in the healthcare and life sciences sector. This agreement, is the latest in a series of venture co-creation (VCC) agreements signed by A*ccelerate to strengthen the start-up ecosystem in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005535/en/ (Photo: Business Wire) Through this agreement, Aptorum Group and A*ccelerate are looking at creating up to 20 deep tech ventures in Singapore over the next five years. These enterprises will leverage technologies co-developed by A*STAR research institutes and Aptorum Group. As part of this agreement, the parties involved will also support the start-ups’ growth through actively nurturing the entrepreneurs. This w

IONITY Fast Charging Network Relies on has·to·be Know-How for the Long Term24.4.2019 13:18:00 EESTTiedote

The IONITY joint venture aims to help electromobility achieve a breakthrough in Europe with a nationwide network of super-fast charging stations. The Austrian electromobility provider, has·to·be, is playing an important role in this. The red-white-red company will take care of the reliable and trouble-free operation of the charging stations. The two companies have agreed on a long-term cooperation so that the expansion of the Europe-wide network can proceed according to plan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005465/en/ has·to·be and IONITY focus on long-term cooperation (Graphic: Business Wire) has·to·be, based in Radstadt (Salzburg), specializes in smart solutions for e-charging stations. For this purpose, the company has developed intelligent software for the management of electrical charging infrastructures. The product is called be.ENERGISED and is used successfully at more than 14,000 charging statio

Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome24.4.2019 13:00:00 EESTTiedote

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome (HES). HES is a rare and often incapacitating disorder with limited treatment options. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees. “We are very pleased to receive orphan drug designation for dexpramipexole for HES,” said Michael Bozik, M.D., CEO of Knopp Biosc

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme